Wipfli Financial Advisors LLC bought a new stake in shares of Syneos Health, Inc. (NASDAQ:SYNH – Get Rating) in the third quarter, Holdings Channel reports. The fund bought 655 shares of the company’s stock, valued at approximately $31,000.
A number of other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Syneos Health by 0.3% during the first quarter. Vanguard Group Inc. now owns 9,724,346 shares of the company’s stock valued at $787,185,000 after acquiring an additional 30,725 shares during the last quarter. Clearbridge Investments LLC raised its holdings in shares of Syneos Health by 5.6% during the second quarter. Clearbridge Investments LLC now owns 4,121,738 shares of the company’s stock valued at $295,446,000 after acquiring an additional 219,576 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Syneos Health by 9.2% during the second quarter. Massachusetts Financial Services Co. MA now owns 3,131,665 shares of the company’s stock valued at $224,478,000 after acquiring an additional 262,865 shares during the last quarter. Cooke & Bieler LP grew its position in shares of Syneos Health by 20.2% in the second quarter. Cooke & Bieler LP now owns 2,836,728 shares of the company’s stock valued at $203,337,000 after purchasing an additional 477,225 shares in the last quarter. Finally, State Street Corp grew its position in shares of Syneos Health by 2.4% in the first quarter. State Street Corp now owns 2,660,420 shares of the company’s stock valued at $215,361,000 after purchasing an additional 61,351 shares in the last quarter. Institutional investors and hedge funds own 93.51% of the company’s stock.
Wall Street Analysts Forecast Growth
SYNH has been the subject of a number of analyst reports. StockNews.com initiated coverage on Syneos Health in a research report on Wednesday, October 12th. They issued a “hold” rating for the company. Barclays lowered Syneos Health from an “overweight” rating to an “underweight” rating and dropped their price target for the company from $30.00 to $25.00 in a research report on Friday, January 13th. Robert W. Baird dropped their price target on Syneos Health from $80.00 to $42.00 and set an “outperform” rating for the company in a research report on Monday, November 7th. Mizuho lowered Syneos Health from a “buy” rating to a “neutral” rating and dropped their price target for the company from $66.00 to $38.00 in a research report on Wednesday, December 14th. They noted that the move was a valuation call. Finally, Deutsche Bank Aktiengesellschaft dropped their price target on Syneos Health from $77.00 to $51.00 in a research report on Wednesday, November 9th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and two have issued a buy rating to the stock. According to MarketBeat, Syneos Health presently has a consensus rating of “Hold” and a consensus target price of $53.60.
Syneos Health Trading Down 0.6 %
Syneos Health (NASDAQ:SYNH – Get Rating) last announced its quarterly earnings data on Thursday, November 3rd. The company reported $1.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.07). The company had revenue of $1.34 billion during the quarter, compared to analyst estimates of $1.37 billion. Syneos Health had a net margin of 5.31% and a return on equity of 14.01%. On average, equities analysts expect that Syneos Health, Inc. will post 4.26 earnings per share for the current year.
Syneos Health Company Profile
Syneos Health, Inc engages in the provision of outsourced clinical development and commercialization services to biopharmaceutical companies. It operates through the following business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers clinical development services spanning Phase I to Phase IV, including global studies, as well as unbundled service offerings such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process.
- Get a free copy of the StockNews.com research report on Syneos Health (SYNH)
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.